

Moderate Expression of Prostate-Specific Membrane Antigen, a Tissue Differentiation Antigen and Folate Hydrolase, Facilitates Prostate Carcinogenesis

Veronica Yao,¹ Anil Parwani,² Christoph Maier,³ Warren DeWayne Heston,⁴ and Dean John Bacich¹

Departments of ¹Urology and ²Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania; ³Mathematics Department, Indiana University of Pennsylvania, Indiana, Pennsylvania; and ⁴Department of Cancer Biology, Lerner Research Institute, Cleveland, Ohio

Abstract

Increased expression of PSMA, a differentiation antigen with folate hydrolase activity, is an independent marker of prostate cancer progression. Mice expressing moderate levels of human PSMA in their prostate develop PIN-like lesions by 9 months. The aim of this study was to determine whether PSMA is involved in prostate carcinogenesis and progression and, if so, the possible mechanism by which PSMA may exert its effects. Using prostates from *PSMA*-transgenic mice, we developed a tissue recombinant model that exhibits small atypical glands with features of adenocarcinoma. This was not observed in tissue recombinants that were composed of prostate tissues from the wild-type siblings. Cells from *PSMA*-transgenic tissue recombinants have the ability to form colonies in semisolid agar. PSMA may facilitate this phenotype by increasing the invasive ability of cells. Ectopic PSMA expression on PC-3 cells increased the invasive capacity of cells in *in vitro* invasion assays, which could be competed out by folic acid. These results suggest PSMA facilitates the development of prostate cancer, and the invasive ability of these cells may be modulated by folate levels. These findings show a novel mechanism that may contribute to the known role of folate in cancer prevention, and may lead to the use of PSMA inhibitors as novel chemopreventive agents for prostate cancer. Moreover, our model should prove useful for further dissecting pathways involved in prostate carcinogenesis and progression. [Cancer Res 2008;68(21):9070–7]

Introduction

Prostate cancer is the most commonly diagnosed cancer and second leading cause of cancer death in American men (1). When compared with all other cancers, the incidence of prostate carcinoma increases most rapidly with age (2). Successful management and elimination of recurrent and metastatic prostate cancer continues to present a major clinical challenge (3).

PSMA, a type II membrane glycoprotein, is expressed in the human prostate and at lower levels in the brain, spine, peripheral nervous system, kidney, small intestine, and the salivary gland (4). PSMA is expressed in the luminal epithelial cells of normal and hyperplastic prostatic tissues, Prostatic Intraepithelial Neoplasia (PIN), and in primary and metastatic prostate cancers (5). Its expression in adenocarcinoma correlates with stage of disease and Gleason score (6, 7). PSMA expression is also higher in cancer cells

from hormone-refractory patients (7, 8). Increased PSMA expression is an independent marker of recurrence (9, 10). Interestingly, endothelial cells of the neovasculature of almost all solid tumors express PSMA but not cells in the neovasculature associated with normal tissues (11–14).

PSMA has glutamate carboxypeptidase II activity that cleaves α -linked glutamate from *N*-acetylaspartyl glutamate (NAALADase activity; ref. 15) and γ -linked glutamates from polyglutamated folates sequentially (folate hydrolase activity; refs. 16, 17). Prostate cancer tissues have significantly elevated levels of PSMA enzymatic activity compared with normal prostate and BPH tissues (18). Increase in both expression and enzymatic activity of PSMA in aggressive prostate tumors imply that PSMA provides a selective advantage for cells expressing it, thereby contributing to the development and progression of prostate cancer.

Transgenic mice have been generated that express human PSMA in their ventral, lateral, and dorsal prostate lobes under the control of the human prostate-specific antigen promoter and enhancer (19). The level of PSMA expressed in the prostates of the transgenic mice is comparable with that in normal human prostate tissues. The level of folate hydrolase activity in the prostate of the transgenic mice is similar to the endogenous level seen in the murine brain and is significantly greater than in the prostates of nontransgenic mice. Characterization of *PSMA*-transgenic mice found that their prostates started to develop PIN-like lesions as early as age 21 weeks, with the majority (above 60%) developing PIN-like lesions by age 9 months. Prostates of the wild-type siblings did not exhibit PIN lesions (19). The presence of PIN-like lesions in *PSMA*-transgenic mice suggests that PSMA plays a role in the control of cell division or transformation, and as such the *PSMA*-transgenic mouse could be a suitable model for examining potential causes of prostate carcinogenesis. However, the length of time for PIN-like lesions to arise in the majority of animals is too long for the model to be cost effective, and thus far, the model has not progressed from PIN lesions to cancer.

The aim of this study was to determine if PSMA is involved in prostate carcinogenesis and progression. We used the prostatic reconstruction model (20) comprising of rat urogenital mesenchyme (rUGM) and prostate tissues from *PSMA*-transgenic mice or their wild-type siblings grafted beneath the renal capsule of immunodeficient mouse hosts and given pharmacologic doses of hormones to achieve our objective. Similar models have been used to show that the absence of *Rb* gene may predispose prostatic epithelial cells to carcinogenesis (21); and to drive PIN lesions in the prostates of *Nkx3.1* knockout mice to a progressively severe histopathologic phenotype (22). Using this model, we were able to elicit carcinogenesis in a timely manner and significantly advance the understanding of the role that PSMA plays in prostate cancer.

Requests for reprints: Dean J. Bacich, University of Pittsburgh Medical Center Shadyside, Department of Urology, 5200 Centre Avenue, Suite G-32, Pittsburgh, PA 15232. Phone: 412-623-3913; Fax: 412-623-3907; E-mail: bacichdj@upmc.edu.

©2008 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-08-2328

We also explored the mechanism by which PSMA plays a role in prostate cancer. Previously, we showed that PSMA provides a growth advantage for prostate cancer cells in medium containing low and physiologic folate levels (23). Ghosh and colleagues (24) found that PSMA-expressing PC-3 cells have reduced invasive capability in RPMI 1640. However, this medium contains ~2.3 $\mu\text{mol/L}$ of folic acid, which is ~100 times the level found at physiologic levels. Therefore, we examined the invasive ability of PC-3 cells that do not express PSMA and those that express PSMA in physiologically relevant folate levels.

Materials and Methods

PSMA-transgenic mouse prostate tissues. Animals were housed in the University of Pittsburgh at the Department of Urology. All animal experiments were approved by and followed the guidelines set out by Institutional Animal Care and Use Committee. *PSMA*-transgenic mice and their wild-type siblings were kindly provided by Dr. Warren Heston (The Cleveland Clinic, Cleveland, OH). Mice (age matched, 27- to 33-wk-old) were killed, and prostates were harvested and microdissected to separate the prostate lobes.

Tissue separation, recombination, and grafting. Rat urogenital sinuses were removed from 18-d embryonic fetuses of pregnant Sprague-Dawley rats (Taconic) and separated into epithelial and mesenchyme components as previously described (20). Prostate lobes from *PSMA*-transgenic mice and wild-type siblings were cut into small (0.2–0.5 mm) pieces and combined with 250,000 rUGM cells in 40 μL neutralized type I rat tail collagen gels as previously described (25). The gels of *PSMA*-transgenic or wild-type prostate tissue recombinants were incubated overnight in RPMI 1640 (Cambrex Corp.) containing 5% fetal bovine serum (FBS; Atlanta Biological) and 10^{-8}M testosterone (Sigma). Tissue recombinants were grafted beneath the renal capsule of adult male nude (Nu/Nu) CD1 mice (Charles River Laboratories) as described previously (20). UGM alone was grafted to determine contamination from urogenital epithelium.

Host nude mice carrying *PSMA*-transgenic or wild-type prostate tissue recombinants were treated hormonally at the time of grafting by implanting s.c. a Silastic capsule [1.54-mm inside diameter and 3.18-mm outside diameter (Dow-Corning Co.)] tightly packed with 25 mg of testosterone propionate (T) and 2.5 mg of 17β -estradiol benzoate (E2; Sigma). Eight weeks postgrafting, host nude mice were killed and each of tissue recombinant was carefully dissected from the host kidney, weighed, and cut into small pieces (0.5–2 mm). Tissue pieces were either paraffin embedded or recombined with fresh rUGM cells in collagen gels and then regrafted for a further 8 wk under the renal capsule of male nude mice. After a total of 16 wk under the renal capsule, the tissue recombinants were recombined with fresh rUGM to again grown under the renal capsule of male nude mouse hosts for a further 8 wk. Animal were treated hormonally with fresh T&E2 upon each sequential serial grafting.

Histopathology and hoechst 33258 dye staining. Tissue sections were stained with H&E for histopathology and Hoechst dye 33258 (Calbiochem) to confirm that the epithelium was of mouse origin and the stroma of rat origin (26). H&E and CK14-stained slides were examined blindly by a pathologist to determine the incidence of normal, hyperplasia, PIN or carcinoma. The most severe histologic phenotype in each tissue recombinant was recorded. PIN-like lesions were scored blindly as 1+, 2+, or 3+ in increasing severity based on their glandular, architectural, and cytologic changes by a pathologist (Dr. A. Parwani).

Immunohistochemical staining and proliferation index. Tissue sections were stained using the Vector M.O.M Peroxidase kit (Vector Laboratories). Nonimmune mouse IgG alone served as the control. Primary antibodies include anti-PSMA (PEQ226.5; Hybritech, Inc.), anti-Cytokeratin 18 (CK18; clone ks18.04; Research Diagnostics, Inc.), anti-CK14 (clone LL001; Abcam), anti-E-cadherin (clone 36; BD Transduction), anti-smooth muscle α -actin (clone 1A4; Sigma), and anti-Ki-67 (clone B56; Research Diagnostics, Inc.). Sections were developed with Vector *NovaRED* Substrate kit (Vector Laboratories). Proliferation index was compiled by manually counting total

epithelial nuclei and epithelial nuclei showing positive immunoreactivity against Ki-67 in microscopic fields. Six to 15 samples were examined using two fields per sample. All photomicrographs were taken using Zeiss Axioplan 2 imaging microscope with an Axiocam and an Axio-Vision software.

Anchorage-independent growth. Tissue recombinants (20 mg) that had been grafted under the kidney capsule for 24 wk were digested with 108 U collagenase for at least 4 h at 37°C and seeded in 6-well plates in a double layer agar culture system. The underlay contained culture medium with a final agar concentration of 0.6% (Difco Laboratories) and the overlay contained culture medium with a final agar concentration of 0.3%. The dishes were incubated at 37°C in a humidified atmosphere, and colonies of >30 cells were counted after 21 d. Photomicrographs were captured on a Nikon T1-SM microscope.

Matrigel invasion assay. PC-3 cells transfected with pLNCX2-PSMA vector or pLNCX2 control vector were maintained in RPMI 1640 [2.3 $\mu\text{mol/L}$ folic acid, called "high folate" (HF)] supplemented with 10% FBS (1.8–2 ng/mL), L-glutamine (2 mmol/L), and penicillin/streptomycin. Folate-free RPMI 1640 supplemented with 10% FBS and penicillin/streptomycin was called "low folate" (1 nmol/L folic acid) medium. Cell invasion assay was performed using the BD BioCoat Matrigel Invasion Chambers (BD Biosciences) as per manufacturer's instructions. Folate-free RPMI 1640 supplemented with 10% FBS, ~25 nmol/L HF medium, L-glutamine, and penicillin and streptomycin was called "physiologic folate" (25 nmol/L folic acid) medium (27). Approximately 2.5×10^4 cells were seeded onto each Matrigel-coated or control (uncoated; 8 μm pore) inserts. The inserts contained either high folate or low folate medium without FBS, whereas the wells were filled with either high folate or low folate medium containing 10% FBS so that the FBS act as the chemoattractant. The chambers were incubated for 22 h at 37°C in a humidified atmosphere of 5% CO_2 . After incubation, the noninvading cells were removed from the upper surface of the membrane by scrubbing with a cotton-tipped swab. The cells that invaded into the lower compartment were stained with 0.5% Crystal Violet/20% methanol and counted. All experiments were done in triplicates. This assay was performed on two different clones of vector-only or PSMA vector transfected PC-3 cells. Data are expressed as the percent invasion through the Matrigel Matrix membrane relative to the migration through the control membrane.

Statistical methods. Statistical analysis on wet weight and proliferation index of the tissue recombinants were done using the Student's *t* test. Wilcoxon Mann-Whitney test was used to analyze incidence of PIN 1+, 2+, and 3+ in wild-type and *PSMA*-transgenic tissue recombinants. The Fisher's exact test was used to analyze the incidence of PIN and foci with features of adenocarcinoma in wild-type and *PSMA*-transgenic tissue recombinants. The Jonckheere-Terpstra test was used to determine whether there is histopathologic progression with serial grafting of the tissue recombinants.

Results

To test if PSMA is involved in prostate carcinogenesis, we grafted tissue recombinants consisting of PSMA-positive or nontransgenic (wild-type) prostate tissues with rUGM under the kidney capsule of host mice also implanted with Silastic tubes containing T&E2. It has previously been shown that implantation of T&E2-filled silastic capsules into nude mice significantly increases their plasma testosterone levels at 1 month and estradiol levels at 2 and 4 months postimplantation (28). Tissue recombinants were harvested after 8, 16, and 24 weeks under the kidney capsule. At each time point, the rUGM control grafts weighed significantly less ($P < 0.05$) than recombinants that included *PSMA*-transgenic or wild-type prostate tissues (Table 1). There was no significant difference in the wet weights between *PSMA*-transgenic and wild-type tissue recombinants; however, the wet weights of both declined with passage (Table 1). The wild-type recombinants grafted for 8 weeks had a larger mean wet weight (103.2 ± 5.2 mg) than recombinants grown for 16 weeks (70.8 ± 11.4 mg), although this did not reach statistical significance ($P > 0.05$). By 24 weeks, the mean wet weight (57.3 ± 8.3 mg) had decreased even further,

resulting in a statistically significant difference in size between wild-type tissue recombinants at week 8 and 24 ($P < 0.01$). Similarly, for *PSMA*-transgenic tissue recombinants, the mean wet weight at 8 weeks (90.2 ± 7.4 mg) was significantly larger than the mean wet weight at 16 weeks (59.6 ± 6.5 mg; $P < 0.01$) and at 24 weeks (62.8 ± 8.7 mg; $P < 0.05$). The decline in wet weights with serial grafting may be due to the limited proliferative capacity of the majority of cells in the tissue recombinants. At no time did the tissue recombinants grow beyond the immediate area of the renal capsule and invade the host kidney.

Both wild-type and *PSMA*-transgenic tissue recombinants formed large masses of well-differentiated prostatic glands surrounded by dense sheets of stromal cells when grown for 8, 16, and 24 weeks under the renal capsule (Fig. 1A, left). As determined by Hoechst 33258 nuclear staining, the epithelial cells were of mouse origin, whereas the stroma was mostly of rat origin (Fig. 1A, right). Their genotypes of wild-type and *PSMA*-transgenic tissue recombinants were confirmed by staining with anti-human *PSMA* antibody (Fig. 1B, top left and top right). Prostatic glands were lined by glandular epithelial cells that expressed CK18 (Fig. 1B, bottom left) and surrounded by stromal cells that expressed smooth muscle α -actin (Fig. 1B, bottom right).

We determined the proliferation index of the recombinant tissue by dividing the number of epithelial cells with Ki-67-stained nuclei by the total number of epithelial cells (Fig. 1C, left). As shown in Fig. 1C (right), the mean proliferation index of *PSMA*-transgenic tissue recombinants was greater than that of wild-type tissue recombinants at week 8, 16, and 24, although this did not reach statistical significance.

Analysis of H&E and CK14 staining of *PSMA*-transgenic tissue recombinants revealed the presence of small atypical glands with features of adenocarcinoma at 16 and 24 weeks (see arrows in Fig. 2). These recombinants also displayed hyperplastic ducts and PIN-like lesions at 8, 16, and 24 weeks (Fig. 2). Ducts with nuclear stratification and/or crowding and rare CK14-expressing basal cells were classified as PIN lesions, whereas adenocarcinoma were defined as small atypical glands with prominent nuclei and nucleoli as well as absence of basal cells as evidenced by negative CK14-staining. PIN-like lesions and some of the small atypical glands expressed E-cadherin along adjacent epithelial cell membranes (Fig. 2). However, other small atypical glands displayed abnormal and variable (weak membrane or cytoplasmic) E-cadherin staining (see arrows in Fig. 2).

In contrast, at no point did we observe adenocarcinoma in the wild-type prostate tissue recombinants, although we did observe

normal, hyperplastic, and focal PIN-like glandular structures (Fig. 2). Normal glands were lined by a single layer of columnar epithelial cells with a continuous layer of CK14-expressing basal epithelial cells. Hyperplastic ducts were lined by multilayered luminal epithelium with a patchy layer of basal cells. Some glands displayed features typical of human PIN, including cribriform, tufted, or papillary architecture of epithelial cells with atypical and hyperchromatic nuclei, enlarged nucleoli (one or more), and mitotic bodies. CK14 staining showed that the PIN-like glands had a patchy basal cell layer (Fig. 2). E-cadherin was expressed along adjacent epithelial cell membranes (Fig. 2).

We next compared the histopathologic features of both types of recombinants at each time point. Although a recombinant may display glands with all histologic types (normal, hyperplasia, PIN, and small atypical glandular foci with features of adenocarcinoma), only the most advanced histologic phenotype found in each of the tissue recombinant was noted. As shown in Table 2, the majority of wild-type tissue recombinants displayed minor PIN-like lesions (PIN 1 and 2) at 8 (78%), 16 (64%), and 24 (79%) weeks. More importantly, none (0%) of the wild-type tissue recombinants displayed glandular foci with features of adenocarcinoma. In contrast, a variable number of small atypical glandular foci with features of adenocarcinoma were present in *PSMA*-transgenic tissue recombinants at 8 (4%), 16 (30%), and 24 (46%) weeks. This difference is statistically significant at 16 ($P = 0.046$) and 24 ($P = 0.012$) weeks but not at 8 ($P = 0.719$) weeks, as determined by the Fisher's exact test. In addition, unlike wild-type tissue recombinants, *PSMA*-transgenic tissue recombinants displayed a statistically significant ($P = 0.0014$) progression from PIN lesions to foci suspicious for adenocarcinoma with serial grafting, as determined by the Jonckheere-Terpstra Test. This is illustrated by a concomitant increase in the number of tissue recombinants with small atypical glands with features of adenocarcinoma (4%, 29%, and 46%) and a decline in the number of recombinants with PIN lesions (96%, 71%, and 50%) as their worst histology over the course of the experiment.

Although both wild-type and *PSMA*-transgenic tissue recombinants displayed PIN-like lesions, the cytologic and pathologic atypia of PIN-like lesions in wild-type tissue recombinants were less severe than those in *PSMA*-transgenic tissue recombinants. PIN-like lesions of both wild-type and *PSMA*-transgenic prostate tissue recombinants were scored blindly by a single pathologist. The classification of PIN lesions was based on their architectural and cytologic atypia. The scale ranged from 1+ to 3+, with 3+ representing the most severe histopathology (see Supplementary Data). PIN-like lesions scored as 1+ (least severe) displayed

Table 1. Wet weights of rat UGM alone, wild-type, and *PSMA*-transgenic prostate tissue recombinants after 8, 16, and 24 wk of kidney grafting in intact male nude host mice treated with testosterone and estradiol


	rUGM only	Wild-type tissue recombinants	<i>PSMA</i> -transgenic tissue recombinants
8 wk	19.2 \pm 4 mg (11)	103.2 \pm 5.2 mg (9)	90.2 \pm 7.4 mg (20)
16 wk	30.4 \pm 5.2 mg (7)	70.8 \pm 11.4 mg (10)	59.6 \pm 6.5 mg (26)*
24 wk	19.7 \pm 3.9 mg (8)	57.3 \pm 8.3 mg (27)*	62.8 \pm 8.7 mg (32)†

NOTE: There was no difference in wet weights of wild-type and *PSMA*-transgenic tissue recombinants. Wet weights of both tissue recombinants declined significantly with serial grafting. Data are reported as mean \pm SE (n).

* $P < 0.01$.

† $P < 0.05$ by Student's *t* test.

Figure 1. Histology and proliferation index of wild-type and *PSMA*-transgenic tissue recombinants. The urogenital mesenchyme microdissected from embryonic day 18 rat fetuses were combined with prostates from either wild-type or *PSMA*-transgenic tissues and grafted underneath the kidney capsules. **A**, wild-type and *PSMA*-transgenic tissue recombinants harvested from a representative host mouse showing size, 8 wk after kidney grafting (*left*). Hoechst 33258 staining of paraffin-embedded tissue recombinants show that the epithelial cells were of mouse origin because they contained several small discrete intranuclear fluorescent bodies, whereas their absence in stromal cells indicates that they are of rat origin (*right*). **B**, immunohistochemical staining of paraffin embedded wild-type (*top left*) and *PSMA*-transgenic (*top right*) tissue recombinants with monoclonal anti-mouse *PSMA* antibody show *PSMA* expression only in *PSMA*-transgenic recombinants. Immunohistochemical staining of paraffin-embedded tissue recombinants with CK18 and smooth muscle α -actin monoclonal antibodies show CK18-expression in luminal epithelial cells (*bottom left*) and α -actin expression in the stromal cells surrounding glandular structures (*bottom right*). Photomicrographs were captured at $\times 20$ magnification. **C**, immunohistochemical staining of paraffin-embedded tissue recombinants with an anti-mouse Ki-67 monoclonal antibody show strong brown nuclear staining of cells undergoing proliferation. Arrows, Ki-67-positive cells (*left*). The cells positive for Ki-67 were counted by monitoring at least 200 luminal epithelial cells for normal, PIN, and carcinoma lesions in multiple regions of the same sample (*right*). There was no difference in the proliferation index of wild-type and *PSMA*-transgenic tissue recombinants grafted beneath the kidney capsule of intact nude mice hosts treated with T&E2 for 8, 16, and 24 wk. Columns, mean ($n = 7$) by Student's *t* test; bars, SE. Photomicrograph was captured at $\times 40$ magnification.



prostatic hyperplasia with the glandular epithelial cells having uniform oval nuclei, some of which were slightly enlarged and/or exhibited weak hyperchromasia. Also, nucleoli were either absent or inconspicuous. PIN-like lesions with a score of 2+ (moderately severe) consisted of glands with moderate hyperplasia, larger cells, higher nucleus to cytoplasmic ratios, more prominent nucleoli, and more pronounced hyperchromasia. Cells with an overall papillary-type architecture displayed more crowding and stratification. Occasionally, a tufted type of architecture was also noted. PIN-like lesions with a score of 3+ (most severe) were characterized by a pronounced increase in cell size, more pleomorphism, striking hyperchromasia with enlarged nucleoli, and some cells contained more than one nucleoli—a feature more commonly seen in neoplasia. There was significant architectural disorder, including the presence of papillary tufts. At low power, these foci were very prominent due to the overall dark, hyperchromatic appearance of the nuclei, giving them an overall dark blue appearance in contrast to adjacent benign glandular structures. In addition, there was significant stratification of the nuclei, giving the appearance of multilayering.

Table 3 summarizes the incidence of 1+, 2+, and 3+ PIN-like in wild-type and *PSMA*-transgenic tissue recombinants. PIN-like lesions present in wild-type tissue recombinants never scored 3+ in severity. In contrast, in the *PSMA*-transgenic tissue recombinants, a score of 3+ was assigned to 23% (5 of 22), 25% (4 of 16), and 54% (7 of 13) of PIN-like lesions at 8, 16, and 24 weeks, respectively. The incidence of PIN 3+ (most severe) in *PSMA*-transgenic tissue recombinants is statistically significant from wild-type prostate tissue recombinants at 8 ($P = 0.00046$), 16 ($P = 0.0334$), and 24 ($P = 0.0000021$) weeks as analyzed with the Wilcoxon Mann-Whitney test statistics. In addition, serial grafting led to a statistical significant ($P = 0.0336$) increase in the number of *PSMA*-transgenic tissue recombinants with PIN 3+ (most severe) as analyzed with the Jonckheere-Terpstra Test.

A hallmark characteristic of tumor cells is their ability to grow in an anchorage-independent manner (29). As shown in Fig. 3A, cells from *PSMA*-transgenic tissue recombinants, which had been grafted under the kidney capsule for 24 weeks, were able to grow and form an average of ~ 5 colonies of >30 cells in semisolid agar. In contrast, cells from wild-type tissue recombinants, which had




Figure 2. PSMA expression promotes cancer formation in mouse prostate recombinants. Paraffin-embedded tissue recombinants grafted for a total of 8, 16, and 24 wk were stained with either CK14 or E-cadherin. A pathologist (Dr. A. Parwani) graded all specimens in blinded fashion. *Arrows*, small atypical glands that lack CK14 (basal cell) expression and display aberrant E-cadherin expression. These prostate glands display features of carcinoma similar to that of human prostate adenocarcinoma. Only *PSMA*-transgenic tissue recombinants were observed to display these small atypical glands with features of adenocarcinoma. Wild-type tissue recombinants displayed PIN-like lesions that have strong CK14 and membrane E-cadherin expressions. Photomicrographs were captured at $\times 40$ magnification.

been grafted under the kidney capsule for 24 weeks, were not able to form colonies of >30 cells in semisolid agar.

We explored the mechanism by which PSMA may influence carcinogenesis by testing the invasive ability of PC-3 cells that do not express PSMA and those that express PSMA in physiologically relevant folate levels. As shown in Fig. 3B, we found that the invasive ability of PC-3 cells with ectopic expression of PSMA were not statistically significant compared with PC-3 cells that do not express PSMA in standard medium, which contains high ($2.3 \mu\text{mol/L}$; percentage invasion: $5.0\% \pm 0.6\%$ and $11.0\% \pm 3.8\%$ versus $7.3\% \pm 0.9\%$ and $7.3\% \pm 4.1\%$) folate levels. However, PSMA-expressing PC-3 cells had increased invasive ability compared with non-expressing PC-3 cells in medium containing low ($<1 \text{ nmol/L}$; $51.7\% \pm 13.0\%$ and $36.0\% \pm 8.7\%$ versus $6.2\% \pm 4.9\%$ and $2.6\% \pm 3.1\%$) and physiologic folate levels (25 nmol/L ; percentage invasion: $14.6\% \pm 3.9\%$ and $11.9\% \pm 2.5\%$ for PSMA-expressing PC-3 cells versus $1.2\% \pm 0.2$ and $5.8\% \pm 2.1\%$ for PC-3 cells transfected with vector only; $P < 0.05$). Two clones of PSMA-expressing PC-3 cells and vector-transfected PC-3 cells were used to confirm the results.

Discussion

PSMA-transgenic mice provide tantalizing preliminary evidence that PSMA contributes to prostate cancer development. However,

PIN-like lesions in *PSMA*-transgenic mice did not progress to cancer. Given that carcinogenesis requires multiple insults, these lesions may not have acquired all of the underlying molecular traits necessary for malignant transformation. Previous work has shown that the tissue recombinant model provides the additional factors needed for cancer development. This model combines hormonal induction of prostate cancer (30–33) with enhanced epithelial proliferation elicited by embryonic rUGM (34–36). We used this model to more definitively evaluate the role of PSMA in prostate carcinogenesis and progression.

Prostatic hyperplasia, PIN, and foci with features of adenocarcinoma were observed in *PSMA*-transgenic tissue recombinants. In contrast, PIN 2+ was the most severe lesion observed in wild-type tissue recombinants, which may be induced by 17β -estradiol. Only *PSMA*-transgenic tissue recombinants developed PIN with the most severe architectural and cytologic atypia, PIN 3+. Serial grafting of the *PSMA*-transgenic, but not wild-type tissue recombinants, resulted in a statistically significant progression in the architectural and cytologic severity from PIN 2+ to PIN 3+. In addition, serial grafting led to progression of the PIN-like lesions in *PSMA*-transgenic tissue recombinants progressed to small atypical glands with features of adenocarcinoma.

Table 2. PSMA expression facilitates formation of small atypical glands with features of cancer, which increase in number with serial grafting

	Epithelium	Normal	Hyperplasia	PIN	Small atypical foci with features of adenocarcinoma
8 wk	Wild-type	1/9 (11%)	1/9 (11%)	7/9 (78%)	0/9 (0%)
	PSMA+	0/23 (0%)	0/23 (0%)	22/23 (96%)	1/23 (4%)
16 wk	Wild-type	0/11 (0%)	4/11 (36%)	7/11 (64%)	0/11 (0%)
	PSMA+	0/23 (0%)	0/23 (0%)	16/23 (70%)	7/23 (30%)
24 wk	Wild-type	2/19 (10.5%)	2/19 (10.5%)	15/19 (79%)	0/19 (0%)
	PSMA+	0/26 (0%)	1/26 (4%)	13/26 (50%)	12/26 (46%)

NOTE: A pathologist determined the incidence of normal, hyperplasia, PIN, and adenocarcinoma in all specimens in a blinded fashion by analyzing H&E and CK14 staining of paraffin-embedded wild-type and *PSMA*-transgenic tissue recombinants. Only *PSMA*-transgenic tissue recombinants displayed small atypical glands with features of adenocarcinoma. The number of these small atypical glands with features of adenocarcinoma increases with serial grafting of the tissue recombinants. The Fisher's exact test was used to analyze the incidence of PIN and foci with features of adenocarcinoma in wild-type and *PSMA*-transgenic tissue recombinants. The Jonckheere-Terpstra test was used to determine whether there is histopathologic progression with serial grafting of the tissue recombinants.

At each time point, the *PSMA*-transgenic tissue recombinants developed small atypical glands that appeared similar to adenocarcinoma. Such small atypical glands were absent in wild-type prostate tissue recombinants and prostate tissues from *PSMA*-transgenic mice. These small atypical glands did not form large masses of back-to-back glands but existed in isolation or in clusters of two to four glands. They exhibited features of adenocarcinoma such as nuclear pleomorphism, prominent and often multiple nucleoli, loss of CK14-expressing basal cells, and aberrant E-cadherin staining. Loss or abnormal E-cadherin expression has been associated with metastasis and poor prognosis (37). The fact that we were able to grow these small atypical cells in semisolid medium (anchorage-independent growth) provides further evidence of their tumorigenicity (38). Similar to Wang and colleagues (21), we were able to transplant the small atypical glands. Moreover, their number increased with serial grafting, suggesting neoplastic progression with successive passage.

In this model, the level of human PSMA expressed in *PSMA*-transgenic prostates is comparable with that found in normal human prostate tissues. In addition, no other genetic manipulations were made that would not be present in normal human prostate

tissue samples before cancer development. Therefore, formation of PIN-like lesions and foci with features of adenocarcinoma in *PSMA*-transgenic prostate recombinants suggests that PSMA, thought to be a cell differentiation marker and not an oncogene or cell cycle regulator, may be an initiator of prostate carcinogenesis.

Previously, Ghosh and colleagues (24) found that ectopic expression of PSMA in PC-3 cells decreased their invasive capability, whereas knockdown of PSMA expression increased the invasiveness of LNCaP cells. They also found that the enzymatic activity of PSMA is associated with the effect of PSMA on invasion. However, their study was conducted in RPMI 1640, which contains ~ 100 times the physiologic folate level. At this concentration, the enzymatic site of PSMA, a folate hydrolase, may be competitively occupied by folic acid, thereby, masking the effects of PSMA. Therefore, we decided to look at the effects of ectopic PSMA expression on the invasive ability of PC-3 cells in RPMI 1640 containing low (<1 nmol/L), physiologic (25 nmol/L), and high (2.3 μ mol/L) folate levels. In contrast to Ghosh and colleagues (24), we counted the number of invading cells 22 hours instead of 48 hours after seeding. We found that PC-3 cells expressing PSMA have greater invasive ability than nonexpressing cells in medium containing low and physiologic folate levels but not

Table 3. PSMA expression facilitates formation of PIN-like lesions with more severe cytologic and histologic features than PIN-like lesions observed in wild-type tissue recombinants

	Epithelium	PIN 1+	PIN 2+	PIN 3+
8 wk	Wild-type	5/7 (71%)	2/7 (29%)	0/7 (0%)
	PSMA+	1/22 (4%)	16/22 (73%)	5/22 (23%)
16 wk	Wild-type	3/7 (43%)	4/7 (57%)	0/7 (0%)
	PSMA+	4/16 (25%)	8/16 (50%)	4/16 (25%)
24 wk	Wild-type	9/15 (60%)	6/15 (40%)	0/15 (0%)
	PSMA+	1/13 (8%)	5/13 (38%)	7/13 (54%)

NOTE: A pathologist scored PIN-like lesions 1+, 2+, and 3+ in increasing pathologic severity in a blinded fashion by analyzing H&E and CK14 staining of paraffin-embedded wild-type and *PSMA*-transgenic tissue recombinants. Although PIN-like lesions were observed in both wild-type and *PSMA*-transgenic tissue recombinants, only *PSMA*-transgenic tissue recombinants displayed PIN-like lesions scored 3+ (most severe) and the number of these lesions increased with serial grafting. The Wilcoxon Mann-Whitney test was used to analyze the incidence of PIN 1+, 2+, and 3+ in wild-type and *PSMA*-transgenic tissue recombinants. The Jonckheere-Terpstra test was used to determine whether there is histopathologic progression with serial grafting of the tissue recombinants.




Figure 3. PSMA expression facilitates formation of cells with the ability to grow in an anchorage-independent manner and ectopic expression of PSMA on prostate cancer cell line increases invasion in medium containing physiologic level of folate. *A*, cells isolated from PSMA-transgenic tissue recombinants that had been grafted under the kidney capsule for 24 wk were able to form colonies of >30 cells on semisolid agar (*left*). In contrast, cells isolated from wild-type tissue recombinants did not form colonies on semisolid agar (*right*). Photomicrographs were captured at $\times 40$ magnification. *B*, PC-3 cells expressing PSMA displayed increased invasive ability compared with PC-3 transfected with vector only in media containing physiologic (25 nmol/L) and low (<1 nmol/L) folate levels compared with those grown in high (normal medium, 2.3 μ mol/L) folate medium. Transwell migration assay was performed using a Boyden chamber system. Data are reported as percent invasion through the Matrigel matrix and membrane relative to the migration through the control membrane; *columns*, mean ($n = 3$); *bars*, SE; *, $P < 0.05$, by Student's *t* test.

in medium containing high folate levels. Increased invasive ability was most prominent in RPMI 1640 containing low (<1 nmol/L) levels of folic acid where prostate cancer cells expressing PSMA had ~10-fold greater percentage invasion than prostate cancer cells transfected with vector only. Based on the data presented here and from our previous study (23), PSMA expression may increase the invasiveness of prostate cancer cells and provide cells with a growth advantage in the low folate tumor microenvironment. The observation that PSMA expression increases invasion, at least under physiologic folate conditions is not without precedent. Conway and colleagues (39) found that angiogenesis is impaired in PSMA-null animals due to reduced invasion of endothelial cells through extracellular matrix.

In conclusion, we have shown that PSMA, expressed at a level comparable with that of normal human prostate tissue and not mutated in any way, can initiate the development of prostate cancer using a hormone-induced tissue recombination model. PSMA may facilitate carcinogenesis by enhancing the proliferative and invasive capability of prostate cancer cells. This invasive capability can be blocked by folic acid. These findings show a novel mechanism that

may contribute to current knowledge about the role of folate in cancer prevention and could potentially lead to the use of PSMA inhibitors as novel chemotherapeutic agents for prostate cancer. Our laboratory is currently using a compound that can inhibit the enzymatic activity of PSMA to investigate if it contributes to the initiation of prostate carcinogenesis.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

Received 6/20/2008; revised 8/25/2008; accepted 9/9/2008.

Grant support: Department of Defense Prostate Cancer Research Program under the award number W81XWH-05-1-0015. Views, opinions, and endorsements by the authors do not reflect those of the US Army or the Department of Defense. This work was also supported by a grant from the AFUD/AUAER Research Scholar Program and the Reston Ambassador's Golf Classic for Prostate Cancer Research Fund.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Simon Hayward for his technical advice and our laboratory technician Diana Sisca Hary.

References

- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. *CA Cancer J Clin* 2008;58:71-96.
- Coffey DS. Prostate cancer: an overview of an increasing dilemma. *Cancer* 1993;71:880-6.
- Walczak JR, Carducci MA. Prostate cancer: a practical approach to current management of recurrent disease. *Mayo Clin Proc* 2007;82:243-9.
- O'Keefe DS, Bacich DJ, Heston WD. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. *Prostate* 2004;58:200-10.
- Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. *Cancer* 1998;82:2256-61.
- Su SL, Huang I-P, Fair WR, Powell CT, Heston WDW. Alternatively spliced variants of prostate-specific membrane antigen RNA ratio of expression as a potential measure of progression. *Cancer Res* 1995;55:1441-3.
- Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by *in situ* hybridization. *Cancer Res* 1997;57:2321-4.
- Wright GL, Jr., Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. *Urology* 1996;48:326-34.
- Ross JS, Sheehan CE, Fisher HAG, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. *Clin Cancer Res* 2003;9:6357-462.
- Mitsiades CS, Lembessis P, Sourla A, Milathianakis C,

- Tsintavis A, Koutsilieris M. Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. *Clin Exp Metastasis* 2004;21:495-505.
11. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. *Clin Cancer Res* 1997;3:81-5.
 12. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. *Cancer Res* 1997;57:3629-34.
 13. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WDW, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. *Clin Cancer Res* 1999;5:2674-81.
 14. Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. *Cancer Res* 1999;59:3192-8.
 15. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptide. *Proc Natl Acad Sci* 1996;93:749-53.
 16. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. *Clin Cancer Res* 1996;2:1445-51.
 17. Tiffany CW, Lapidus RG, Merion A, Calvin DC, Slusher BS. Characterization of the enzymatic activity of PSM: comparison with brain NAALADase. *Prostate* 1999;39:28-35.
 18. Lapidus RG, Tiffany CW, Isaacs JT, Slusher BS. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. *Prostate* 2000;45:350-4.
 19. Bacich DJ, Harsch KM, Heston WD. Transgenic mice expressing human Prostate-Specific Membrane Antigen (PSMA) in their prostate: A potential model for prostate cancer initiation, development and therapy. In: *Proceedings of the American Association for Cancer Research Annual Meeting*. San Francisco 2002.
 20. Cunha GR, Donjacour AA. Mesenchymal-epithelial interactions: technical considerations. In: Coffey DS, Bruchovsky N, Gardner WA, Resnick MI, Karr JP, editors. *Assessment of Current Concepts and Approaches to the Study of Prostate Cancer*. New York: A R. Liss; 1987. pp. 273-82.
 21. Wang Y, Hayward SH, Donjacour AA, et al. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. *Cancer Res* 2000;60:6008-17.
 22. Kim MJ, Bhatia-Gaur R, Banach-Petrovsky WA, et al. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. *Cancer Res* 2002;62:2999-3004.
 23. Yao V, Bacich DJ. Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in physiologically relevant folate environment in vitro. *Prostate* 2006;66:867-75.
 24. Ghosh A, Wang X, Klein E, Heston WD. Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. *Cancer Res* 2005;65:727-31.
 25. Hallows RC, Bone EJ, Jones W. A new dimension in the culture of human breast. In: Richards RJ, Rajan KT, editors. *Tissue culture in medical research*. Oxford: Pergamon Press; 1980. pp. 213-20.
 26. Cunha GR, Vanderslice KD. Identification in histological sections of species origin of cells from mouse, rat and human. *Stain Technol* 1984;59:7-12.
 27. Chanarin I. The folate in vitamins in medicine. Baker BM, Bender DA, editors. London: Heinemann Medical Books; 1980. p. 247-314.
 28. Ricke WA, Ishii K, Ricke EA, et al. Steroid hormones stimulate human prostate cancer progression and metastasis. *Int J Cancer* 2006;118:2123-31.
 29. Freedman VH, Shin SI. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. *Cell* 1974;3:355-9.
 30. Wang YZ, Wong YC. Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. *Prostate* 1998;35:165-77.
 31. Noble RL. Prostate cancer of the Nb rat in relation to hormones. *Int Rev Exp Pathol* 1980;23:113-59.
 32. Isaacs JT, Furuya Y, Berges R. The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. *Semin Cancer Biol* 1994;5:391-400.
 33. Hayashi N, Cunha GR, Parker M. Permissive and instructive induction of adult rodent prostatic epithelium by heterotypic urogenital sinus mesenchyme. *Epithelial Cell Biol* 1993;2:66-78.
 34. Triche TJ, Harkin JC. An ultrastructural study of hormonally induced squamous metaplasia in the coagulating gland of the mouse prostate. *Lab Investigation* 1971;25:596-606.
 35. Wang Y, Sudilovsky D, Zhang B, et al. A human prostatic epithelial model of hormonal carcinogenesis. *Cancer Res* 2001;61:6064-72.
 36. Cunha GR, Sekkingstad M, Meloy BA. Heterospecific induction of prostatic development in tissue recombinants prepared with mouse, rat, rabbit, and human tissues. *Differentiation* 1983;24:174-80.
 37. Umbas R, Isaacs WB, Bringuier PP, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. *Cancer Res* 1994;54:3929-33.
 38. Colburn NH, Bruegge WF, Bates JR, et al. Correlation of anchorage-independent growth with tumorigenicity of chemically transformed mouse epidermal cells. *Cancer Res* 1978;38:624-34.
 39. Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. *Mol Cell Biol* 2006;26:5310-24.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Moderate Expression of Prostate-Specific Membrane Antigen, a Tissue Differentiation Antigen and Folate Hydrolase, Facilitates Prostate Carcinogenesis

Veronica Yao, Anil Parwani, Christoph Maier, et al.

Cancer Res 2008;68:9070-9077.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/68/21/9070>

Cited articles This article cites 35 articles, 15 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/68/21/9070.full#ref-list-1>

Citing articles This article has been cited by 3 HighWire-hosted articles. Access the articles at:
<http://cancerres.aacrjournals.org/content/68/21/9070.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.